Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with SOX as first-line treatment for advanced gastric cancer
ChiCTR1800017837Phase 4Not yet recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Gansu Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800017837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017837.